Jolene Johnson, MD Associate Clinical Professor of Medicine, LSU School of Medicine Head, Statewide Diabetes Disease Management, LSU HCSD.

Slides:



Advertisements
Similar presentations
Earl K. Long Medical Center Diabetic Retinal Eye Screening Mary Campos RN, CDE Diabetes Care Manager January 25, 2011.
Advertisements

Whats wrong with a piece of paper? The Electronic Transfer of Care Princess of Wales Hospital Rowena Lewis.
Welcome to the new acute and community County Durham and Darlington NHS Foundation Trust Clinical strategy FT member events April 2011.
SAFETY NET NETWORK LEADERSHIP AND ADVISORY GROUP MEETING Wednesday, June 19, 2013.
13 th Annual Forum on Health Care Effectiveness 14 th Annual Forum on Health Care Effectiveness January 25, 2011.
Disclosure I, Peter T. Katzmarzyk, PhD, FACSM, have no relationships with commercial interests to disclose. A commercial interest is any entity producing,
Jolene Johnson, MD Associate Clinical Professor of Medicine, LSU School of Medicine Head, Statewide Diabetes Disease Management, LSU HCSD Diabetes Disease.
Louisiana State University Hospital- Based Longitudinal Study (LSUHLS) Gang Hu, MD, MPH, PhD, FAHA Pennington Biomedical Research Center.
Chicken Soup for the Busy Coordinator Nov 2010 PROTOCOL FEASIBILITY.
YALE MASTER SLIDE HERE Clinical Research Management – Is not just a handshake deal? Jamie Caldwell, MBA Director Office of Research Services for the Health.
1. 2 Implementing and Evaluating of an Evidence Based Nursing into Practice Prepared By Dr. Nahed Said El nagger Assistant Professor of Nursing H.
A Survey of Research Experience and Interests among Practice Based Research Network Providers Lisa Schrader MT MBA, Rod Erickson MD, David Warner MD, Tom.
SYNOPSIS OF THE PROTOCOL Title: Pregnancy Associated Breast Cancer (PABC); Prospective Data Registry in Saudi Arabia Sponsor: Oncology Department, King.
How to Find and Access Clinical Trials New Treatments, No Tricks A Seminar on Minority Participation in Clinical Trials June 15, 2010.
Paula Peyrani, MD Medical/Project Director, HIV Program at the 550 Clinic Assistant Director, Research Design and Development Clinical and Translational.
Pat F. Bass III, MD CMIO LSU-Health Shreveport ICON Steering Committe.
PROJECT INSPIRE NYC Hep C Taskforce Meeting May 20,
Darren A. DeWalt, MD, MPH Division of General Internal Medicine Maihan B. Vu, Dr.PH, MPH Center for Health Promotion and Disease Prevention University.
Evaluating A Patient-Centered Medical Home from the Patient’s Perspective Betty M. Kennedy, PhD Community Outreach Specialist Community Outreach Specialist.
Prospective Telemedicine Screening for Diabetics at High Risk for Retinopathy. PI- Jayne S Weiss, MD LSUHSC-NO.
Peter T. Katzmarzyk, PhD, FACSM Associate Executive Director for Population Science Professor and Louisiana Public Facilities Authority Endowed Chair Pennington.
Designing Screening Protocols for Diabetes and Pre-diabetes Ron Horswell, PhD (PBRC) Gang Hu, MD PhD (PBRC) Study group: Jolene Johnson, MD (LSU HSC) Will.
® From Bad to Worse: Comorbidities and Chronic Lower Back Pain Margaret Cecere JD, Richard Young MD, Sandra Burge PhD The University of Texas Health Science.
BioMedical Informatics Core Update ICON Annual Meeting, April 22, 2013 Ron Horswell, PhD Associate Professor Pennington Biomedical Research Center.
Rangel PDSA TB Didactic TB or not TB?. AIM Statement In order to improve care at the Charles Rangel Clinic, we will implement a tuberculosis screening.
Health Care Cost Database Presented by the Office of the Commissioner of Securities and Insurance January 2011.
... for our health Wisconsin Research and Education Network and the University of Wisconsin Department of Family Medicine Collaboration Among Pharmacists.
Impact of the “Asthma Toolbox” for Improving Documentation of Pediatric Asthma Management in an Urban Community Health Center Presenter: Delaney Gracy,
Determining the Impact of Diabetes on Health and Independence of Individuals with Dementia Dr Jeffrey N Keller (PI) Pennington Biomedical Research Center.
2008© COPYRIGHT Thrombosis and Hemostasis Centers Research and Prevention Network Centers for Disease Control & Prevention Thomas L. Ortel, M.D., Ph.D.
Smear negative TB and HIV: urgent research priorities to inform a rolling global policy Haileyesus Getahun, MD, MPH, PhD Stop TB Department WHO/HQ.
RESIDENT PROJECTS ROBERT LEONHARD QUALITY IMPROVEMENT MANAGER.
ABSTRACT Diabetes is a public health issue of growing magnitude. It currently ranks among the top ten leading causes of death in the United States. To.
SARC: Participation and Protocol / Concept Review Robert Maki, MD PhD Memorial Sloan-Kettering Cancer Center.
Cancer Centers In Clinical Trials Sandrine Marreaud Head of Medical Department.
Clinical Assessment Program for Residencies Jim Czarnecki, D.O.
Nursing Process- Implementaton. Implementation Implementation is a category of nursing behavior in which the actions necessary for accomplishing the health.
The NCI Central IRB Initiative Third Annual Medical Research Summit Washington, D.C. March 2003.
Lee Arcement, MD, MPH. Donabedian’s Quality Triangle-It’s Relevance to Process Improvement -Avedis Donabedian, MD, MPH ( )
The Wisconsin Network for Health Research (WiNHR): Overview. An Infrastructure for Conducting Multi-Site Clinical Research across the State of Wisconsin.
How To Design a Clinical Trial
Office Redesign to Increase Prevention Services? Give “PEAs” a Chance Cheryl B. Aspy, Ph.D. Professor, Family & Preventive Medicine OUHSC – College of.
First Annual Meeting. Project Development Teams: Concept and Example Scott C. Denne, M.D. Professor of Pediatrics Associate Director of the Indiana CTSI.
Inside Clinical Trials ® ALL RIGHTS RESERVED. What is a clinical trial? ALL RIGHTS RESERVED.
How to Start An Industry Sponsored Clinical Trial
Evaluation Plan Steven Clauser, PhD Chief, Outcomes Research Branch Applied Research Program Division of Cancer Control and Population Sciences NCCCP Launch.
Glaucoma Care Project Team Members: Geoffrey T. Emerick, M.D. Erin Herlihy, B.S. Marilyn Hauser, M.B.A. Dianna Greening, R.N. Walter M. Jay, M.D Opportunity.
NCCCP Pilot – Clinical Trials Ann O’Mara, PhD, RN, FAAN Program Director Community Clinical Oncology Program Division of Cancer Prevention June 26, 2007.
Levels of Review of Research and Quality Improvement Walter Kraft, MD Associate Director, Office of Human Subjects Protection Department of Pharmacology.
PRACTICE TRANSFORMATION NETWORK 2/24/ Transforming Clinical Practice Initiative (TCPI) Practice Transformation Network (PTN)  $18.6 million –
Improving the Quality of Prenatal Care at the WMed FM Residency Clinic Susan Jevert, DO Homer Stryker MD School of Medicine Department of Family and Community.
CHILDREN OF PRISONERS PARTNERSHIP What is the Children of Prisoners (CP) Partnership? The CP Partnership is a funding project between PFI and selected.
Depression Screening in Primary Care and Impact on Suicide Prevention Anne-Marie T. Mann, BSN, RN, DNP Candidate Diane Kay Boyle, PhD, RN, FAAN.
An Inter-Professional Collaboration between a Family Medicine Center and a School of Nursing Maritza De La Rosa, MD New Jersey Family Practice Center Rutgers,
WA Stroke Data Collection Data specifications/Definitions Andy Wu Senior Policy Officer Subacute Community & Aged Care Directorate.
Risk Factors for Candida dubliniensis Bloodstream Infections Katherine Veltman, B.S., Peggy L. Carver, Pharm.D, FCCP The University of Michigan Health.
© Coherent market Insights. All Rights Reserved PEDIATRIC CLINICAL TRIALS MARKET Global Industry Insights, Outlook Size, Share and Opportunity Analysis,
For Official Use Only-I1-A1
Clinicaltrials.gov Update
The FDA Early Feasibility Study Pilot and the Innovation Pathway
Leigh E. Tenkku, PhD, MPH Department of Family and Community Medicine
Daniela B. Friedman, University of South Carolina
Severe Chronic Conditions Substantial Service Needs
Use of Real-World Data in Clinical Drug Development
Victoria Gemmell1 Professor Alex Mullen2
Cindy Murray NP Princess Margaret Cancer Centre
ACCORD Update/Training Event The Changing Research Landscape 26th February 2019 Heather Charles Head of Research Governance.
IMPACT QIC Action Period Call
SYNOPSIS OF THE PROTOCOL
Assigning Risk Categories to Patients
Presentation transcript:

Jolene Johnson, MD Associate Clinical Professor of Medicine, LSU School of Medicine Head, Statewide Diabetes Disease Management, LSU HCSD

Benefits of LSU ICON for Diabetes Disease Management Project Design and Protocol Development IRB Submissions and Approvals Database Development and Management Data Analysis/Statistical Support Dedicated Patient Interaction Specialists to Assist in Recruitment and Data Collection

Diabetes Interest Group – Assisting Diabetes Management Group in the development and testing of procedures associated with the expansion of the scope of its programs and services Diabetes Screening Techniques Treatment Strategies for Pre-Diabetes Hepatitis B Immunization Benefits of LSU ICON for Diabetes Disease Management

Current LSU ICON Diabetes Disease Management Projects Implementing Screening for Diabetes and Pre-Diabetes within the LSU HCSD Medical Home Clinics Jolene Johnson, MD and Ronald Horswell, PhD Principal Investigators Jay Besse, BS and Rob Leonhard, MBA Co-Investigators Designing Screening Algorithms for Diabetes and Pre-Diabetes Ronald Horswell, PhD Principal Investigator Gang Hu, MD, PhD and Jolene Johnson, MD Co-Investigators

Implementing Screening for Diabetes and Pre-Diabetes within the LSU HCSD Medical Home Clinics Overview: This Quality Improvement project pilots a specific diabetes screening protocol and follow-up program. This pilot was conducted at three LSU HCSD medical home clinics. If the pilot protocol and follow-up program prove feasible and sustainable, they will be implemented at other LSU HCSD medical home clinics.

Implementing Screening for Diabetes and Pre-Diabetes within the LSU HCSD Medical Home Clinics Specific Aims: Aim 1: Pilot at three LSU HCSD Medical Home clinics a new diabetes screening program that consists of using the newly-developed LSU Diabetes/Pre-diabetes Screening Protocol (Screening Protocol) to identify previously undiagnosed diabetes patients and pre-diabetes patients. Aim 2: Assess the feasibility and sustainability of the screening program. If Aim 2 demonstrates feasibility and sustainability of the screening program, or suggests feasibility and sustainability can be achieved with only minor modifications, the project will move on to Aims 3 and 4. Aim 3: Implement (via a phased roll-out) the screening program (Screening Protocol and Follow-up Protocol) across LSU Health medical home clinics. Aim 4: Evaluate the clinical effectiveness of the screening program.

Implementing Screening for Diabetes and Pre-Diabetes within the LSU HCSD Medical Home Clinics Project was piloted for 2,830 patients who visited three Medical Home Clinics at Earl K. Long from January 14, 2013 to February 28, – North Baton Rouge – South Baton Rouge – Family Practice Clinic

Implementing Screening for Diabetes and Pre-Diabetes within the LSU HCSD Medical Home Clinics Exclusion by Administration Data ? Screened? Screening stop boxes for exclusion? Yes No Yes No Unique visitors (2830) A Visitors (1714) D Screened (841) F Existing Diabetes Diagnosis (75) G Recently Tested (371) H Ordered (190) M Done (130) O Age<45 & BMI<25 (51) I Normal (55) Q Pre-diabetes (63) R Diabetes (12) S Pending (60) P Not Ordered (22) N 2+ Risk Factors (212) K Not screened (873) E Diabetes (817) B Less than 2 Risk Factors (132) L Cancer, HIV or ESRD (299) C Risk Factors Assessed (344 ) J Group Name (# of subjects) Decision Legend

Results: 5.7% Prevalence of previously undiagnosed patients with diabetes identified among those with two or more risk factors visiting the pilot clinics Based upon the LSU HCSD Medical Home volume of 101,000 unique adult patients annually, 1420 patients would be identified by the screening protocol as having diabetes if conducted for one year Implementing Screening for Diabetes and Pre-Diabetes within the LSU HCSD Medical Home Clinics

Results: 29.9% Prevalence of previously undiagnosed pre-diabetic patients among those with two or more risk factors visiting the pilot clinics. Based upon the LSU HCSD Medical Home volume of 101,000 unique adult patients annually, 7,470 patients would be identified by the screening protocol as having pre-diabetes if conducted for one year Implementing Screening for Diabetes and Pre-Diabetes within the LSU HCSD Medical Home Clinics

Overall Impact of Projects on Improvement of Health Outcomes The identification of a large number of undiagnosed patients with pre-diabetes highlights the need for a treatment strategy. Therefore, feasible and inexpensive interventions for patients with pre-diabetes should be defined and tested.

Current LSU ICON Diabetes Disease Management Projects Implementing Screening for Diabetes and Pre-Diabetes within the LSU HCSD Medical Home Clinics Jolene Johnson, MD and Ronald Horswell, PhD Principal Investigators Jay Besse, BS and Rob Leonhard, MBA Co-Investigators Designing Screening Algorithms for Diabetes and Pre-Diabetes Ronald Horswell, PhD Principal Investigator Gang Hu, MD, PhD and Jolene Johnson, MD Co-Investigators

Designing Screening Algorithms for Diabetes and Pre-Diabetes Overview: This Quality Improvement Project is gathering data necessary to evaluate alternative screening algorithms for identifying previously undiagnosed patients with diabetes and pre-diabetes. The immediate application of these results will be the development of a cost effective screening algorithm(s) for use within the LSU Health delivery system.

Designing Screening Algorithms for Diabetes and Pre-Diabetes Specific Aims Aim 1: Estimate and compare the achievable combinations of sensitivity and specificity obtainable by the candidate screening protocols involving single or multiple component tests. Aim 2: Determine if risk factor assessment via either the American Diabetes Associations risk factor instrument and/or the FINDRISC instrument improves screening algorithm performance. Aim 3: Conduct cost effectiveness analysis comparing the candidate algorithms.

DETERMINING CLINICAL DIABETES DIAGNOSIS Designing Screening Algorithms for Diabetes and Pre-Diabetes

Results: Risk factor screening instruments, utilized as typically recommended (e.g.: ADA 2+ risk factors), reduce the cost per person screened, but have a maximum sensitivity of 80%. Suggests the need to be selective in establishing screening instrument cut off points.

Overall Impact of Project on Improvement of Health Outcomes To maximize the sensitivity and minimize the cost of diabetes screening

Comparing Cost Effectiveness of Two Methodologies for Assessing Diabetic Patients for Hepatitis B Vaccines Within the Medical Home Clinic Jolene Johnson, MD and Ronald Horswell, PhD Principal Investigators Proposed LSU ICON Diabetes Disease Management Project

Overview: Two general strategies for Hepatitis B vaccination – Test for immunity prior to vaccination – Immunize all patients Critical information for determining optimal strategy includes: – Cost of immunity testing – Cost of immunization – Baseline prevalence of immunity in the population Proposed LSU ICON Diabetes Disease Management Project